Table 2. Morbidity outcomes and recurrence analysis.
| Variable | OX-HIPEC, n=61 | OX-HIPEC + EPIC, n=24 | OXIRI-HIPEC, n=48 | Whole cohort, n=133 | P value |
|---|---|---|---|---|---|
| Morbidity | |||||
| Return to OR postop, n [%] | 6 [10] | 4 [17] | 4 [8] | 14 [11]* | 0.4 |
| Clavien-Dindo grade 3–4, n [%] | 19 [31] | 7 [29] | 9 [19] | 35 [26] | 0.2 |
| 3 | 15 [25] | 7 [29] | 7 [15] | 29 [22] | |
| 4 | 4 [6] | 0 [0] | 2 [4] | 6 [4] | |
| In-hospital mortality, n [%] | 1 [2] | 1 [4] | 0 [0] | 2 [2] | |
| Any grade neutropenia, n [%] | 1 [2] | 6 [25] | 21 [44] | 28 [21] | <0.0001 |
| Recurrences at 24 months | |||||
| Systemic recurrence | 18 [30] | 9 [37] | 21 [44] | 48 [36] | 0.2 |
| Missing data | 8 [13] | 7 [29] | 5 [10] | 20 [15] | |
| Peritoneal recurrences | 30 [49] | 7 [29] | 16 [33] | 53 [40] | 0.08 |
| Missing data | 5 [8] | 1 [4] | 3 [6] | 9 [7] | |
| Secondary analysis: single drug HIPEC vs. multiple drug HIPEC | Single drug HIPEC, n=61 | Multiple drug HIPEC (OX EPIC and OXIRI), n=72 | |||
| Return to OR postop, n [%] | 6 [10] | 8 [11] | 14 [11]* | 0.9 | |
| Clavien-Dindo grade 3–4, n [%] | 19 [31] | 16 [22] | 35 [26] | 0.3 | |
| Peritoneal recurrences, n [%] | 30 [49] | 23 [32] | 53 [40] | 0.051 | |
*, Reasons for re-operation (n=14): 2 bleeding, 2 anastomotic leakage, 2 sepsis unclear abdominal cause, 3 small bowel or gastric perforations, 2 wound dehiscence, 1 mesh-caused bowel obstruction, 1 unclear severe postop pain, 1 ureter perforation. HIPEC, hyperthermic intraperitoneal chemotherapy; OX-HIPEC, oxaliplatin-based HIPEC; EPIC, post-operative intraperitoneal chemotherapy; OXIRI-HIPEC, oxaliplatin-irinotecan-based HIPEC; OR, operating room.